|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Buy||Buy||Buy||Buy||Buy|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||30||Current|
|Doji Star Bearish||1W||Current|
|Bullish Engulfing||30||2||Dec 15, 2017 14:30|
|Rising Three Methods||15||4||Dec 15, 2017 14:45|
|Engulfing Bearish||1W||7||Oct 22, 2017|
|Dr. Reddy's Labs||2,371.50||2,380.00||2,316.45||+60.85||+2.63%||743.68K||15:49:59|
|Tata Steel Ltd||694.70||700.85||691.05||+8.95||+1.31%||3.16M||15:43:32|
|Mahindra & Mahindra||1,483.40||1,490.00||1,441.00||+51.80||+3.62%||3.55M||15:57:00|
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.Read More
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.